JOURNAL ARTICLE

Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study

Matheus Vieira, Solène Buffier, Mathieu Vautier, Alexandre Le Joncour, Yvan Jamilloux, Mathieu Gerfaud-Valentin, Laurence Bouillet, Estibaliz Lazaro, Stéphane Barete, Laurent Misery, Delphine Gobert, Tiphaine Goulenok, Olivier Fain, Karim Sacre, Pascal Sève, Patrice Cacoub, Cloé Comarmond, David Saadoun
Frontiers in Immunology 2020, 11: 626792
33613571

Objective: Mucocutaneous and joint disorders are the most common manifestations in Behçet's syndrome (BS) and are frequently clustered in the so-called minor forms of BS. There remains a need for safe and effective treatment for joint lesions in BS. We report the long-term safety and effectiveness of apremilast in refractory joint and mucocutaneous manifestations of BS.

Methods: French nationwide multicenter study including 50 BS patients with either active joint and/or mucocutaneous manifestations resistant to colchicine and/or DMARDs. Patients received apremilast 30 mg twice a day. Primary effectiveness endpoint was the proportion of patients with complete response (CR) of articular symptoms at month 6 (M6), defined as resolution of inflammatory arthralgia and arthritis, with joint count equal to zero.

Results: At inclusion, the median tender and swollen joint count was of 4 [2-6] and 2 [1-2], respectively. The proportion of CR in joint disease at M6 was 65% (n = 15/23), and 17% (n = 4/23) were partial responders. CR of oral and genital ulcers, and pseudofolliculitis at M6 was 73% (n = 24/33), 94% (n = 16/17) and 71% (n = 10/14), respectively. The overall response at M6 was 74% for the entire cohort and 70% for the mucocutaneous-articular cluster (n = 27). The median Behçet's syndrome activity score significantly decreased during study period [50 (40-60) vs. 20 (0-40); p < 0.0001]. After a median follow-up of 11 [6-13] months, 27 (54%) patients were still on apremilast. Reasons for apremilast withdrawal included adverse events (n = 15, 30%) and treatment failure (n = 8, 16%). Thirty-three (66%) patients experienced adverse events, mostly diarrhea (n = 19, 38%), nausea (n = 17, 34%) and headache (n = 16, 32%).

Conclusion: Apremilast seems effective in BS-related articular disease refractory to colchicine and DMARDs. Discontinuation rates were significantly higher than that reported in clinical trials.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Responses

Sort by: Most RecentHighest Rated

Christoph Haller

Gelenke, nach 6 Monaten 2/3 besser

OZT Stopp war häufiger als in den klinischen VorStudien

0

Christoph Haller

AM: real life, Nationwide.
Alle auf Apremilast, bei therapierefraktärität.
Colchizin bei fast allen, DMARDs 50%. 1/3 PDN.

OTZ teil in Kombination gegeben (Colchizin, MTX).

OTZ auf Gelenke: 2/3 in kompletter Gele ks Remission (!)

46% hatten OTZ gestoppt (NW)

0

Trending Papers

Remove bar
Read by QxMD icon Read
33613571
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"